Cargando…
Erratum on ‘‘Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective”
Autores principales: | Salvino, M.A., Bonfim, C., Calado, R.T., Kim, H., Bertinato, J.F., Scheinberg, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096252/ http://dx.doi.org/10.1016/j.htct.2022.04.001 |
Ejemplares similares
-
Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016) -
Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022) -
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
por: Tremblay, Gabriel, et al.
Publicado: (2019) -
Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019) -
Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)